3B Blackbio Dx Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

3B Blackbio Dx Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with 3B Blackbio Dx shares trading at Rs.1,197 against a market capitalisation of Rs.1,034 Cr and a price-to-earnings multiple of Not meaningful. As a healthcare services name on the NSE and BSE, 3B Blackbio Dx enters the 3B Blackbio Dx Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

Quarterly financials for 3B Blackbio Dx are not yet fully available on Univest’s data partners for this cycle; investors should track Screener.in and the NSE/BSE filings directly for the 3B Blackbio Dx Q1 Results FY27 result date and cross-check any figures before making investment decisions.

Get Free Investment Predictions and 3B Blackbio Dx Research at Univest

3B Blackbio Dx (NSE: 3BBLACKBIO) operates in the healthcare services space and is tracked on Univest under its NSE and BSE listings ahead of the 3B Blackbio Dx Q1 Results FY27 season, forming the base against which the 3B Blackbio Dx Q1 Results FY27 estimates in this article are built. This 3B Blackbio Dx Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

3B Blackbio Dx Q1 FY27 Estimates

Metric	Detail
CMP	Rs.1,197
Market Cap	Rs.1,034 Cr
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.1,209-1,365

Univest, a SEBI-Registered Investment Advisor, Tracks 3B Blackbio Dx Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. Occupancy and ARPOB Trends

Occupancy and ARPOB improvement across hospital and diagnostic networks is one of the primary variables that analysts are tracking ahead of 3B Blackbio Dx’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the 3B Blackbio Dx share price target or faces renewed pressure.

2. Capacity Addition

Capacity addition through new beds or centres supporting medium-term growth is one of the primary variables that analysts are tracking ahead of 3B Blackbio Dx’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the 3B Blackbio Dx share price target or faces renewed pressure.

3. Case Mix Improvement

Case mix improvement toward higher-margin specialties aiding profitability is one of the primary variables that analysts are tracking ahead of 3B Blackbio Dx’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the 3B Blackbio Dx share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track 3B Blackbio Dx’s live price and Q1 FY27 result updates.

Key Risks to the 3B Blackbio Dx Q1 Results FY27 Outlook

• Slower occupancy ramp-up in newly added capacity affecting near-term margins.
• Regulatory changes to pricing or insurance reimbursement norms.
• Talent cost inflation for specialist doctors and clinical staff.

Recent Performance Context

Detailed recent-quarter financials for 3B Blackbio Dx were not available from Univest’s data partners at the time of writing. Investors should check Screener.in or the company’s exchange filings for the latest verified numbers before the Q1 FY27 results.

Technical Analysis Ahead of 3B Blackbio Dx Q1 Results FY27

3B Blackbio Dx shares last traded at Rs.1,197. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the 3B Blackbio Dx Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the 3B Blackbio Dx Q1 Results FY27 trailing-growth framework points to a range of Rs.1,174-1,270 for 3B Blackbio Dx, contingent on the 3B Blackbio Dx Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this 3B Blackbio Dx Q1 Results FY27 view for 3B Blackbio Dx works out to Rs.1,209-1,365, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into 3B Blackbio Dx Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this 3B Blackbio Dx Q1 Results FY27 analysis would put 3B Blackbio Dx in a Rs.1,276-1,491 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the 3B Blackbio Dx Q1 Results FY27 Print

• Revenue and PAT versus the 3B Blackbio Dx Q1 Results FY27 estimate range in this preview.
• Management commentary on FY27 growth guidance and margin trajectory relevant to the 3B Blackbio Dx Q1 Results FY27 narrative.
• Occupancy and ARPOB improvement across hospital and diagnostic networks
• Slower occupancy ramp-up in newly added capacity affecting near-term margins

Conclusion on 3B Blackbio Dx Q1 Results FY27

3B Blackbio Dx enters the Q1 FY27 results season trading at Rs.1,197, with the 12-month Uniresearch target range of Rs.1,209-1,365 reflecting a tracking stance. Investors tracking the 3B Blackbio Dx Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

FAQs on 3B Blackbio Dx Q1 Results FY27

When are 3B Blackbio Dx Q1 FY27 results expected?

Ans. 3B Blackbio Dx’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the 3B Blackbio Dx Q1 FY27 revenue estimate?

Ans. Detailed quarterly estimates are not available for 3B Blackbio Dx at this time; check Screener.in or the company’s exchange filings for verified numbers.

What is the 3B Blackbio Dx share price target?

Ans. The 12-month Uniresearch estimate for 3B Blackbio Dx share price target is Rs.1,209-1,365, based on trailing growth and current valuation multiples.

Is 3B Blackbio Dx a good buy before Q1 FY27 results?

Ans. 3B Blackbio Dx is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in 3B Blackbio Dx’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and occupancy and ARPOB improvement across hospital and diagnostic networks.

Where can I track 3B Blackbio Dx share price live?

Ans. 3B Blackbio Dx share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.